News Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Real-time Estimate Cboe BZX Other stock markets 03:32:14 2024-04-25 pm EDT			5-day change	1st Jan Change
155.6 ^USD	-2.16%		-4.78%	+25.86%

Apr. 22	Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung	CI
Apr. 16	Stifel Adjusts Price Target on Krystal Biotech to $204 From $178, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung	Apr. 22	AQ
Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung	Apr. 22	CI
Stifel Adjusts Price Target on Krystal Biotech to $204 From $178, Maintains Buy Rating	Apr. 16	MT
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting	Apr. 05	AQ
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting	Apr. 04	AQ
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing	Mar. 12	MT
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing	Mar. 12	MT
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference	Feb. 29	AQ
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference	Feb. 28	AQ
Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 26	MT
Sector Update: Health Care Stocks Weaker Monday Afternoon	Feb. 26	MT
Top Midday Gainers	Feb. 26	MT
Krystal Biotech Shares Jump After Surprise Q4 Profit	Feb. 26	MT
Krystal Biotech Swings to Q4 Profit as Company Generates Revenue; Shares Climb Pre-Bell	Feb. 26	MT
Transcript : Krystal Biotech, Inc., Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
Krystal Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
Earnings Flash (KRYS) KRYSTAL BIOTECH Posts Q4 EPS $0.30, vs. Street Est of $-0.25	Feb. 26	MT
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates	Feb. 26	AQ
Krystal Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
North American Morning Briefing : Traders Await Inflation Data This Week	Feb. 26	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Summary

Filters